BNTX
BioNTech SE
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-6/100
Last price
95.86
▼ 1.78 (1.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
98.45
Prev close
97.64
Day high
100.02
Day low
95.31
Volume
899.36K
Market cap
$24.05B
P/E (TTM)
—
52W range
79.52 – 124.00
Day trading desk
Gap from prior close
+0.83%
Prior close 97.64
VWAP
96.85
-1.02% from price
Relative volume
0.71×
Normal
Session range
5.17%
95.10 – 100.02
Position in range
15%
Near session low
ATR (14D)
3.15
3.29% of price
Prior day high
98.79
PDH
Prior day low
95.20
PDL
Bid / ask spread
—
Quote not published
Session volume
821.81K
Avg 1.16M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.88%
-4.8%
1M
-7.74%
-8.9%
3M
+2.35%
-2.2%
6M
+6.82%
-11.4%
YTD
+0.56%
-13.7%
1Y
-9.25%
-25.7%
3Y
-11.88%
-94.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BNTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
143.79M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 66.00K | $6.48M | Direct |
| Sep 28, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 61.00K | $6.01M | Direct |
| Sep 24, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 69.00K | $6.84M | Direct |
| Sep 22, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 79.00K | $7.86M | Direct |
| Sep 16, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 49.00K | $4.72M | Direct |
| Sep 14, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 86.00K | $8.44M | Direct |
| Sep 10, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 20.50K | $1.97M | Direct |
| Sep 9, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 73.00K | $7.19M | Direct |
| Sep 4, 26 | SAHIN UGUR MD Chief Executive Officer |
SELL | 76.50K | $7.89M | Direct |
| Apr 22, 26 | POETTING SIERK Chief Operating Officer |
SELL | 50.00K | $5.53M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
POETTING SIERK |
Chief Operating Officer | — | Sale |
SAHIN UGUR MD |
Chief Executive Officer | 39.43M | Sale |
Fundamentals
Market cap$24.05B
Enterprise value$10.90B
Revenue (TTM)$2.65B
Gross profit$2.03B
EBITDA$-1.38B
Net income$-1.69B
EPS (TTM)$-7.67
Free cash flow$-249.56M
Total cash$13.46B
Total debt$316.10M
Book value / share$79.29
Shares outstanding251.20M
Float109.10M
Short % of float3.48%
Dividend yield0.00%
Beta (5Y)1.25
Valuation & profitability ratios
Trailing P/E—
Forward P/E-17.37
PEG ratio0.05
Price / sales—
Price / book1.21
EV / revenue4.11
EV / EBITDA-7.89
Gross margin76.62%
Operating margin-806.63%
Profit margin-63.64%
Return on equity-9.30%
Return on assets-5.41%
Debt / equity1.78
Current ratio7.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.87B | $2.75B | $3.82B | $17.31B | +4.3% |
| Operating revenue | $2.87B | $2.75B | $3.82B | $17.15B | +4.3% |
| Cost of revenue | $641.80M | $541.30M | $599.80M | $3.00B | +18.6% |
| Gross profit | $2.23B | $2.21B | $3.22B | $14.32B | +0.8% |
| Research & development | $2.10B | $2.25B | $1.78B | $1.54B | -6.6% |
| Selling, general & admin | $698.20M | $712.70M | $587.10M | $541.20M | -2.0% |
| Total operating expense | $2.87B | $2.92B | $2.34B | $2.01B | -1.7% |
| Operating income | -$640.70M | -$709.40M | $875.60M | $12.30B | +9.7% |
| Net interest income | -$12.60M | -$17.20M | -$7.50M | -$18.90M | +26.7% |
| Pre-tax income | -$1.05B | -$677.70M | $1.19B | $12.95B | -55.1% |
| Tax provision | $85.30M | -$12.40M | $255.80M | $3.52B | +787.9% |
| Net income | -$1.14B | -$665.30M | $930.30M | $9.43B | -70.8% |
| Net income to common | -$1.14B | -$665.30M | $930.30M | $9.43B | -70.8% |
| Basic EPS | -4.70 | -2.77 | 3.87 | 38.78 | -69.7% |
| Diluted EPS | -4.70 | -2.77 | 3.83 | 37.77 | -69.7% |
| EBIT | -$1.04B | -$660.80M | $1.19B | $12.97B | -56.9% |
| EBITDA | -$653.80M | -$362.80M | $1.38B | $13.10B | -80.2% |
| Basic shares | 241.70M | 240.40M | 240.60M | 243.28M | +0.5% |
| Diluted shares | 241.70M | 240.40M | 242.70M | 249.79M | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.68B | $9.76B | $11.66B | $13.88B | -21.4% |
| Cash & short-term investments | $14.88B | $16.78B | $16.55B | $14.06B | -11.4% |
| Accounts receivable | $924.20M | $1.46B | $2.16B | $7.15B | -36.9% |
| Inventory | $110.70M | $283.30M | $357.70M | $439.60M | -60.9% |
| Total current assets | $16.15B | $18.80B | $19.53B | $21.92B | -14.1% |
| Property, plant & equipment | $1.29B | $1.18B | $971.60M | $821.10M | +9.1% |
| Goodwill & intangibles | $1.97B | $1.17B | $1.17B | $219.70M | +68.6% |
| Total assets | $21.99B | $22.53B | $23.01B | $23.28B | -2.4% |
| Total current liabilities | $2.14B | $2.52B | $2.07B | $2.95B | -15.1% |
| Current debt | $52.20M | $39.50M | $28.10M | $36.00M | +32.2% |
| Long-term debt | $215.20M | $214.70M | $191.00M | $176.20M | +0.2% |
| Total debt | $267.40M | $254.20M | $219.10M | $212.20M | +5.2% |
| Total liabilities | $2.76B | $3.12B | $2.76B | $3.22B | -11.4% |
| Retained earnings | $17.96B | $19.10B | $19.76B | $18.83B | -5.9% |
| Shareholder equity | $19.22B | $19.41B | $20.25B | $20.06B | -1.0% |
| Working capital | $14.00B | $16.28B | $17.46B | $18.97B | -14.0% |
| Net tangible assets | $17.25B | $18.24B | $19.08B | $19.84B | -5.4% |
| Shares issued | 259.03M | 248.55M | 248.55M | 248.55M | +4.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.05B | -$677.70M | $1.19B | $12.95B | — | -55.1% |
| Depreciation & amortisation | $382.80M | $298.00M | $183.40M | $123.30M | — | +28.5% |
| Stock-based compensation | $106.20M | $100.90M | $51.40M | $108.60M | — | +5.3% |
| Change in working capital | $537.80M | $1.22B | $5.57B | $4.52B | — | -55.9% |
| Operating cash flow | $456.00M | $207.70M | $5.37B | $13.58B | — | +119.5% |
| Capital expenditure | -$749.00M | -$452.30M | -$705.50M | -$363.30M | — | -65.6% |
| Investing cash flow | -$2.47B | -$2.08B | -$6.95B | -$35.30M | — | -18.6% |
| Share buybacks | $0 | $0 | -$738.50M | -$986.40M | — | — |
| Dividends paid | — | $0 | $0 | -$484.30M | $0 | — |
| Financing cash flow | -$52.90M | -$45.90M | -$778.60M | -$1.42B | — | -15.3% |
| Free cash flow | -$293.00M | -$244.60M | $4.67B | $13.21B | — | -19.8% |
| End cash position | $7.68B | $9.76B | $11.66B | $13.88B | — | -21.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $105.60M | $118.10M | $907.40M | $1.52B | $260.80M | -10.6% |
| Operating revenue | $51.90M | $66.90M | $1.12B | $1.47B | $153.30M | -22.4% |
| Cost of revenue | $97.00M | $71.40M | $333.30M | $148.30M | $76.40M | +35.9% |
| Gross profit | $8.60M | $46.70M | $574.10M | $1.37B | $184.40M | -81.6% |
| Research & development | $551.00M | $557.00M | $505.40M | $564.80M | $509.10M | -1.1% |
| Selling, general & admin | $197.80M | $163.80M | $291.70M | $148.50M | $137.40M | +20.8% |
| Total operating expense | $947.30M | $717.90M | $854.60M | $716.70M | $656.40M | +32.0% |
| Operating income | -$938.70M | -$671.20M | -$280.50M | $653.90M | -$472.00M | -39.9% |
| Net interest income | $62.70M | $57.00M | -$5.10M | -$300.00K | $64.00M | +10.0% |
| Pre-tax income | -$858.70M | -$568.10M | -$227.40M | $24.70M | -$402.70M | -51.2% |
| Tax provision | -$37.90M | -$36.20M | $77.60M | $53.40M | -$16.10M | -4.7% |
| Net income | -$820.80M | -$531.90M | -$305.00M | -$28.70M | -$386.60M | -54.3% |
| Net income to common | -$820.80M | -$531.90M | -$305.00M | -$28.70M | -$386.60M | -54.3% |
| Basic EPS | -3.24 | -2.10 | -1.25 | -0.12 | -1.60 | -54.3% |
| Diluted EPS | -3.24 | -2.10 | -1.25 | -0.12 | -1.60 | -54.3% |
| EBIT | -$855.20M | -$564.10M | -$676.40M | $653.90M | -$399.00M | -51.6% |
| EBITDA | -$589.10M | -$442.80M | -$511.60M | $778.10M | -$348.00M | -33.0% |
| Basic shares | 253.33M | 253.29M | 244.00M | 239.17M | 241.63M | +0.0% |
| Diluted shares | 253.33M | 253.29M | 244.00M | 239.17M | 241.63M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.74B | $9.94B | $7.68B | $10.09B | $10.27B | -2.0% |
| Cash & short-term investments | $14.78B | $14.64B | $14.88B | $14.52B | $14.04B | +1.0% |
| Accounts receivable | $163.90M | $539.20M | $924.20M | $690.80M | $1.37B | -69.6% |
| Inventory | $100.60M | $103.80M | $110.70M | $225.70M | $230.70M | -3.1% |
| Total current assets | $15.30B | $15.53B | $16.15B | $15.83B | $15.93B | -1.5% |
| Property, plant & equipment | $1.22B | $1.32B | $1.29B | $1.24B | $1.24B | -7.6% |
| Goodwill & intangibles | $1.79B | $1.92B | $1.97B | $1.75B | $1.85B | -6.4% |
| Total assets | $20.34B | $21.07B | $21.99B | $21.34B | $21.64B | -3.5% |
| Total current liabilities | $1.95B | $1.76B | $2.14B | $2.22B | $1.85B | +10.4% |
| Current debt | $57.20M | $10.80M | $52.20M | $53.40M | $52.40M | +429.6% |
| Long-term debt | $258.90M | $66.60M | $215.20M | $192.00M | $217.20M | +288.7% |
| Total debt | $316.10M | $302.80M | $267.40M | $245.40M | $269.60M | +4.4% |
| Total liabilities | $2.59B | $2.38B | $2.76B | $2.86B | $3.13B | +8.8% |
| Retained earnings | $16.61B | $17.43B | $17.96B | $18.27B | $18.30B | -4.7% |
| Shareholder equity | $17.76B | $18.70B | $19.22B | $18.48B | $18.51B | -5.0% |
| Working capital | $13.35B | $13.77B | $14.00B | $13.61B | $14.08B | -3.0% |
| Net tangible assets | $15.96B | $16.78B | $17.25B | $16.73B | $16.65B | -4.9% |
| Shares issued | 251.20M | 259.03M | 259.03M | 248.55M | 248.55M | -3.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$858.70M | -$568.10M | -$227.40M | $24.70M | -$402.70M | -51.2% |
| Depreciation & amortisation | $266.10M | $121.30M | $164.80M | $124.20M | $51.00M | +119.4% |
| Stock-based compensation | $20.90M | $22.80M | $24.10M | $27.90M | $32.10M | -8.3% |
| Change in working capital | $593.90M | $66.20M | -$227.40M | $644.00M | $519.70M | +797.1% |
| Operating cash flow | $10.50M | -$421.00M | $309.50M | $780.70M | $146.50M | +102.5% |
| Capital expenditure | -$55.40M | -$78.90M | -$62.10M | -$38.60M | -$30.20M | +29.8% |
| Investing cash flow | -$100.10M | $2.65B | -$2.73B | -$925.30M | -$64.40M | -103.8% |
| Share buybacks | -$129.20M | — | — | — | $0 | — |
| Financing cash flow | -$108.50M | $26.40M | -$14.30M | -$11.50M | -$13.30M | -511.0% |
| Free cash flow | -$44.90M | -$499.90M | $247.40M | $742.10M | $116.30M | +91.0% |
| End cash position | $9.74B | $9.94B | $7.68B | $10.09B | $10.27B | -2.0% |
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
60.00
-37.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
852
Contracts, this expiry
Put volume
148
Contracts, this expiry
Heaviest call OI
80.00
0 contracts
Heaviest put OI
60.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.08 | -2.22 | -6.8% |
| Mar 2026 | -1.92 | -1.95 | -1.6% |
| Dec 2025 | -0.25 | -0.33 | -30.4% |
| Sep 2025 | 0.10 | -0.12 | -220.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.76 | 5 | $1.06B | -30.0% |
| Next quarter | -0.75 | 5 | $503.38M | -44.5% |
| Current year | -4.65 | 9 | $1.81B | -37.0% |
| Next year | -4.91 | 9 | $1.81B | +0.2% |
Analyst targets & ownership
Mean target$116.02
High target$139.70
Low target$73.23
Implied upside21.03%
Analyst count20
ConsensusBUY
Strong buy / Buy1 / 13
Hold5
Sell / Strong sell0 / 1
Held by insiders57.24%
Held by institutions20.45%
Institutions holding476
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
97.93
-2.11% from price
SMA 20
97.78
-2.09% from price
SMA 50
98.78
-3.09% from price
SMA 100
94.95
+0.95% from price
SMA 200
97.75
-2.06% from price
EMA 12
97.77
-1.96% from price
EMA 26
98.51
-2.69% from price
EMA 50
98.12
-2.30% from price
RSI (14)
43.0
Neutral
MACD (12,26,9)
-0.74
Hist -0.26
ATR (14)
3.15
3.29% of price
Realised vol 30D
36.5%
Annualised
Bollinger upper
100.39
20, 2σ
Bollinger lower
95.16
20, 2σ
50 / 200 cross
Golden
98.78 vs 97.75
Trend bias
Below 200
-2.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.90
Less volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
36.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.7%
Peak to trough
Max drawdown 5Y
-78.4%
Peak to trough
ATR 14
3.15
3.29% of price
Beta (reported)
1.25
5Y monthly, from filing
Short interest
Shares short
2.32M
Prior 2.51M
Change vs prior
-7.4%
Shorts covering
% of float
3.48%
Normal
% of shares out
0.92%
Against total outstanding
Days to cover
1.4
Liquid
Float
109.10M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | BMO Capital | DOWNGRADE | Outperform | Market Perform |
| Aug 31, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 8, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 27, 26 | UBS | UPGRADE | Neutral | Buy |
| May 22, 26 | Bernstein | INITIATED | — | Market Perform |
| May 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 6, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Apr 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 10, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Mar 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateJun 2, 2022
Next pay dateJun 17, 2022
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-18
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-08-28
Corporate Changes & Voting Matters
6-K · 2026-08-27
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-08-04
Corporate Changes & Voting Matters
6-K · 2026-08-03
Periodic Financial Reports
20-F/A · 2026-07-30
Headlines
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
24/7 Wall St. · 11h ago
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
24/7 Wall St. · 1d ago
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
24/7 Wall St. · 6d ago
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Zacks · 7d ago
How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
Simply Wall St. · 10d ago
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Insider Monkey · 12d ago
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Barrons.com · 13d ago
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
24/7 Wall St. · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.